AHB(SH:688639) Mei Ri Jing Ji Xin Wen·2025-07-30 23:15Group 1 - Huaheng Biological plans to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to advance its globalization strategy and enhance brand influence and core competitiveness [1] - The company aims to optimize its capital structure and broaden financing channels by leveraging international capital market resources [1] - The listing process is subject to board and shareholder approval, as well as regulatory review by the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1] Group 2 - Nossger's ongoing equity dispute is nearing resolution as the Supreme People's Court rejected the retrial application from the plaintiff, Zhong Dafa [2] - The company stated that the lawsuit has not impacted its current or future profits, although it may have affected external reputation and investor confidence [2] Group 3 - East China Pharmaceutical's subsidiary, China-US East, received acceptance for its application for the marketing authorization of Edaravone tablets for treating acute ischemic stroke [3] - If approved, Edaravone tablets will enhance the company's cardiovascular product pipeline and may replace existing injection forms, creating market opportunities [3] Group 4 - Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, following a significant stock price fluctuation [4] - The acquisition is still in the planning stage, with no agreements signed yet, leading to uncertainty regarding its implementation [4] - The company has not identified any insider trading activities among executives or major shareholders during this period [4]